PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. Rationale and design of a randomised, open, phase III, clinical trial with blinded outcome assessment

Hendrik Reinink1,*, Jeroen C de Jonge1,*, Philip M Bath2, Diederik van de Beek3, Eivind Berge4, Saskia Borregaard5, Alfonso Ciccone6, Laszlo Csiba7, Jacques Demotes8, Diederik W Dippel9, Janika Körv10, Iwona Kurkowska-Jastrzebska11, Kennedy R Lees12, Malcolm R Macleod13, George Ntaios14, Gary Randall15, Götz Thomalla16 and H Bart van der Worp1

Abstract

Background: Elderly patients are at high risk of complications after stroke, such as infections and fever. The occurrence of these complications has been associated with an increased risk of death or dependency.

Hypothesis: Prevention of aspiration, infections, or fever with metoclopramide, ceftriaxone, paracetamol, or any combination of these in the first four days after stroke onset will improve functional outcome at 90 days in elderly patients with acute stroke.

Design: International, 3 × 2-factorial, randomised-controlled, open-label clinical trial with blinded outcome assessment (PROBE) in 3800 patients aged 66 years or older with acute ischaemic stroke or intracerebral haemorrhage and an NIHSS score ≥ 6. Patients will be randomly allocated to any combination of oral, rectal, or intravenous metoclopramide (10 mg thrice daily); intravenous ceftriaxone (2000 mg once daily); oral, rectal, or intravenous paracetamol (1000 mg four times daily); or usual care, started within 24 h after symptom onset and continued for four days or until complete recovery or discharge from hospital, if earlier.

1Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus Institute, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
2Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK
3Department of Neurology, Academic Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands
4Department of Internal Medicine, Oslo University Hospital, Oslo, Norway
5Clinical Trial Center North GmbH, Hamburg, Germany
6Department of Neurology and Stroke Unit, ASST di Mantova, Mantua, Italy
7Department of Neurology, University of Debrecen, Debrecen, Hungary
8European Clinical Research Infrastructure Network (ECRIN), Paris, France
9Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
10Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia
112nd department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland
12Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
13Division of Clinical Neurosciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
14Department of Medicine, Larissa University Hospital, University of Thessaly, Larissa, Greece
15Stroke Alliance for Europe (SAFE), Brussels, Belgium
16Department of Neurology, Center for Clinical Neurosciences, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

*The first two authors contributed equally to this paper

Corresponding author:
H Bart van der Worp, Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, CX Utrecht 3584, The Netherlands.
Email: H.B.vanderWorp@umcutrecht.nl
Outcome: The primary outcome measure is the score on the modified Rankin Scale at 90 days (± 14 days), as analysed with multiple regression.

Summary: This trial will provide evidence for a simple, safe and generally available treatment strategy that may reduce the burden of death or disability in patients with stroke at very low costs.

Planning: First patient included in May 2016; final follow-up of the last patient by April 2020.

Registration: ISRCTN, ISRCTN82217627, https://doi.org/10.1186/ISRCTN82217627

Keywords
Stroke, complications, elderly, ceftriaxone, metoclopramide, paracetamol

Date received: 22 January 2018; accepted: 28 March 2018

Introduction
In the first days after stroke, about half of all patients develop complications, including infections and fever. The risk of developing these events is greater in patients of higher age or with more severe stroke.1–3 Aspiration, infections and fever can impede functional recovery, prolong hospital admissions, and are independently associated with an increased risk of death or long-term dependency.1,2,4–9 In addition, systematic review of animal studies modelling ischaemic stroke has shown that hyperthermia during or shortly after the onset of ischaemia substantially increases infarct size, suggesting that the relation between fever and poor outcome observed in patients is at least in part causal.10

The risk of developing these complications can be reduced by very simple, safe and inexpensive measures, such as metoclopramide for the management of dysphagia, antibiotics for the prevention of infections and paracetamol for the prevention of fever, but it is uncertain whether these measures also improve functional outcome.11–14 In some, generally small, randomised trials, preventive treatment with these drugs not only convincingly reduced the risks of aspiration, infections, or fever by one third to one half, but was also associated with clear trends towards a lower risk of death or poor outcome.11–14 The cluster-randomised Quality in Acute Stroke Care (QASC) study demonstrated that implementation of nursing protocols for the management of fever, hyperglycaemia and swallowing dysfunction on a stroke unit resulted in better outcomes.15 However, in two recent large trials, preventive treatment with antibiotics did not improve functional outcomes.16,17

American guidelines for the treatment of patients with acute ischaemic stroke advocate screening for dysphagia; the use of antibiotics in patients with infections; and antipyretic drugs such as paracetamol in patients with subfebrile temperatures or fever.18 Guidelines of the European Stroke Organisation concluded that there is insufficient evidence from randomised trials to make strong recommendations on whether, when and to whom preventive antibiotic or antipyretic treatment should be given after ischaemic stroke or intracerebral haemorrhage.19,20 The authors called for randomised trials to allow for better-informed recommendations in the future.20

The PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke (PRECIOUS) trial will assess whether a pharmacological strategy to prevent aspiration, infections, or fever with metoclopramide, ceftriaxone, paracetamol, or any combination of these in elderly patients with a moderately severe to severe acute stroke is more effective at reducing the risk of death and improving functional outcome than current clinical practice of waiting until these complications are manifest before initiating treatment.

Design
Overview and timelines
PRECIOUS is an international, multi-centre, 3 × 2-factorial, randomised, controlled, open-label clinical trial with blinded outcome assessment (PROBE) of the preventive use of metoclopramide, ceftriaxone, paracetamol, or any combination of these, for four days in elderly patients with acute ischaemic stroke or intracerebral haemorrhage. The primary outcome measure is the score on the modified Rankin Scale (mRS) at 90 days (±14 days).21 3800 patients will be recruited over a period of about four years in about 80 hospitals (both academic and regional) in 9 European countries (Figure 1). The first patient was included in May 2016 and the main results are anticipated to be available in 2020. The complete and most recent version of the study protocol is available at www.precious-trial.eu.
Study population

The study population consists of patients aged 66 years or older who are hospitalised with moderately severe to severe acute ischaemic stroke or intracerebral haemorrhage and can be treated within 24 h of stroke onset. In order to be eligible to participate, a patient must meet all inclusion criteria listed in Table 1 and none of the exclusion criteria listed in Table 2. Patients with an active infection are excluded.

Patient enrolment

After written informed consent, patients are randomly allocated in a 3 × 2 factorial design to any combination of open-label oral, rectal, or intravenous metoclopramide (10 mg thrice daily); intravenous ceftriaxone (2000 mg once daily); oral, rectal, or intravenous paracetamol (1000 mg four times daily); or usual care, started within 24 h after symptom onset and continued for four days or until complete recovery or discharge from hospital, if earlier (Figure 2). The daily dose of metoclopramide is reduced to 3 times 5 mg in patients with moderate to severe renal impairment or with severe hepatic impairment, and to 3 times 2.5 mg in patients with end-stage renal disease.

Allocation is based on proportional minimisation through a web-based allocation service. Treatment allocation is stratified by country and includes the following minimisation factors for balance in baseline characteristics: age (66–75 years vs. > 75 years); sex (male vs. female); stroke type (ischaemic stroke vs. intracerebral haemorrhage); stroke severity (NIHSS 6–12 vs. > 12); and diabetes mellitus (yes vs. no). Investigators have the opportunity to censor a single randomisation stratum in a specific patient before randomisation, for example in case of an allergy to one of the study medications (Table 2). Alongside the study treatment, all patients receive standard care as recommended by national or international guidelines or local protocols. This may include thrombolysis and endovascular treatment for acute ischaemic stroke, and treatment of hypertension for intracerebral haemorrhage.

Data collection and follow-up

Baseline characteristics assessed are listed in Table 3. The presence of any treatment restriction, the method of food intake and the vital signs (including body temperature) are recorded at baseline and during the first seven days of hospitalisation. The recording and reporting period for all severe or serious adverse events begins after randomisation and ends on day 7, except for serious adverse reactions and suspected unexpected serious adverse reactions (SUSARs), which are recorded and reported up to 90 days. Death occurring before day 90 (± 14) is a study secondary outcome and is always documented and recorded.

At day 7 after admission to the hospital, or at discharge if earlier, the score on the mRS is assessed. During a follow-up visit at day 90 (± 14), the mRS is assessed by a trained, certified investigator in a standard fashion according to each centre’s normal practice, and the interview is recorded with a digital video camera. During this recording, no reference to the treatment allocation is made. The videos are uploaded and distributed for independent and blinded scoring by three certified expert raters from the same country as the patient. Additionally, the Barthe index (BI),22 Montreal Cognitive Assessment (MoCA)23 and EuroQol 5D-5L (EQ-5D-5L) are assessed at 90 days.
**Table 2.** Exclusion criteria.

1. Active infection requiring antibiotic treatment\(^a\)
2. Pre-stroke score on the mRS $\geq 4$\(^b\)
3. Death appearing imminent at the time of assessment

Criteria for censoring a treatment stratum:

For the metoclopramide stratum:
1. Hypersensitivity to metoclopramide or to any of the excipients;
2. Gastrointestinal haemorrhage, mechanical obstruction or gastro-intestinal perforation for which the stimulation of gastrointestinal motility constitutes a risk;
3. Confirmed or suspected pheochromocytoma;
4. History of neuroleptic or metoclopramide-induced tardive dyskinesia;
5. Epilepsy;
6. Parkinson's disease;
7. Use of levodopa or dopaminergic agonists;
8. Known history of methaemoglobinemia with metoclopramide or of NADH cytochrome-b5 deficiency.
9. Clinical indication for the use of metoclopramide. Incidental use of metoclopramide before screening is not an exclusion criterion.

For the ceftriaxone stratum:
1. Known hypersensitivity to beta-lactam antibiotics;
2. Clinical indication for antibiotic treatment. The use of an antibiotic before screening is not an exclusion criterion.

For the paracetamol stratum:
1. Known hypersensitivity to paracetamol or any of the excipients;
2. Known severe hepatic insufficiency;
3. Chronic alcoholism;
4. Clinical indication for the use of paracetamol. Incidental use of paracetamol before screening is not an exclusion criterion.

mRS: modified Rankin Scale.

\(^a\)As judged by the treating clinical physician.

\(^b\)Score 4 mRS: Moderately severe disability. Unable to attend to own body needs without assistance and unable to walk unassisted.

---

**Figure 2:** Treatment allocation will be based on proportional minimisation. Investigators will have the opportunity to censor a single randomisation stratum in a specific patient before randomisation. Each of the 8 subgroups is expected to consist of approximately 475 patients.
Table 3. Baseline characteristics.

- Demographics: age; sex; ethnicity
- Comorbidities/medical history: atrial fibrillation; diabetes mellitus; hypertension; pre-stroke mRS
- Concurrent drugs: use of any antipyretic, antibiotic, or antiemetic drug in the three days before randomisation.
- Way of food intake on the day before the stroke
- Treatment restrictions
- Dates and times: stroke onset, hospital admission
- Vital signs: blood pressure; pulse; body temperature
- Neurological examination: NIHSS; location of the lesion
- Laboratory examinations:
  - Results of chest X-ray and urine analysis if performed as part of routine clinical practice
  - Imaging results: stroke type: ischaemic stroke or intracerebral haemorrhage
  - Previous treatment: intravenous thrombolysis with alteplase; intra-arterial treatment.

mRS: modified Rankin Scale; NIHSS: National Institutes of Health Stroke Scale.

Aspirin in any formulation and in a daily dose of up to 300 mg is not considered an antipyretic drug.
The method of feeding on the day before the stroke and at noon of the relevant day will be recorded and classified as 1. normal food; 2. oral, soft or fluids only; 3. nasogastric tube; 4. percutaneous endoscopic gastrostomy (PEG); 5. intravenous only; 6. none.
The presence of any treatment restriction will be recorded at baseline and during the patients stay in the hospital, and will be classified as 1. Do not resuscitate; 2. Do not intubate and ventilate; 3. Withholding other treatments that may prolong life; 4. Withholding food; 5. Withholding fluids; and 6. Palliation with morphine or a benzodiazepine. Any combination of these strategies is possible.
Blood pressure, pulse and body temperature will be assessed at baseline and at 12-h (± 3 h) intervals (where assessed as part of routine clinical practice). Both rectal and tympanic thermometry are allowed.

Table 4. Study outcomes.

Primary outcome
- Score on the mRS

Secondary outcomes
- At 7 days (± 1 day) or at discharge, if earlier:
  - Infections in the first seven days (± 1 day; frequency, type and C. difficile infections)
  - 3rd generation cephalosporin resistance in the first seven days (± 1 day)
  - Antimicrobial use during the complete hospital admission for stroke
- SAEs in the first seven days
- In a subgroup of patients: presence of ESBL-producing bacteria.

At 90 days (± 14 days):
- Death
- Unfavourable functional outcome
- Disability
- Cognition
- Quality of life
- Home time
- Patient location

Outcome events

The primary outcome measure is the score on the mRS at 90 days (±14). The mRS is an ordinal hierarchical scale incorporating seven categories from 0 up to and including 6 and describes the range of disability encountered post stroke. ‘Death’ is assigned a score of 6. Secondary outcomes are outlined in Table 4.

Infections will be categorised as diagnosed by the clinician, and as judged by an independent adjudication committee (masked to treatment allocation) according to modified Centres for Disease Control and Prevention criteria. The scoring algorithms for infections that will be used by this committee have been described previously and are in line with recommendations of the Pneumonia in Stroke Consensus Group. Clostridium difficile infection will be defined as diarrhoea in combination with a positive Clostridium difficile toxin test.

Substudy

To detect selection of bacteria with third generation cephalosporin resistance caused by increased antibiotic pressure, a nested case-control substudy will be
Sample size calculation and statistical analysis plan

The primary effect estimate will be the difference between groups in the mRS scores obtained through centralised adjudications and assessed using multiple regression, and will be expressed as a mean difference with 95% confidence interval. PRECIOUS is powered to detect a statistically significant shift in the difference in the proportion of patients with mRS 0 to 2 at 90 days, assuming an effect that leads to a 5% absolute increase from 36 to 41% in the cumulative proportion of patients with mRS 0 to 2 in any intervention group, compared with controls. The effect size of 5% is based on previous smaller studies and/or meta-analyses thereof, performed in more general stroke populations.\textsuperscript{12–14,16} The statistical analyses will be performed according to the intention-to-treat principle and adjusted for the minimisation factors mentioned, other relevant baseline characteristics, and treatment allocation for the other two strata of the trial. Three separate primary analyses will be performed, looking at the main effects of each of the three interventions compared with their respective controls. Although the study is not powered to detect interactions between the three interventions, such interactions will be investigated in secondary analyses. Two sensitivity analyses will be performed in which all patients who are lost to follow-up will be classified as having the worst possible outcome (death) or the best possible outcome (mRS = 0), respectively.

Secondary efficacy outcomes will be analysed using similar methods as for the primary efficacy analysis, with binary logistic regression used for binary outcomes, including death, unfavourable outcome and SAEs. Ordinal logistic regression will be used for ordered categorical data and multiple regression for continuous outcomes. Wilcoxon signed rank sum test will be used for continuous outcome measures which are not normally distributed. Several subgroup analyses will be performed based on age, sex, stroke type and severity, diabetes mellitus, presence of atrial fibrillation, pre-stroke mRS score, treatment with alteplase or other recanalisation method, treatment allocation for the other two trial strata and time to treatment. A full statistical analysis plan will be completed before the final follow-up of the last patient.

Discussion

Because several complications in the first days after stroke have consistently been associated with a higher risk of death or poor functional outcome, prevention of these complications appears a logical, simple and safe approach to improve outcome after stroke. In the past two decades, several trials aimed at prevention of complications have been performed, but – besides organised care in a designated stroke unit – no treatment to prevent complications has convincingly shown to improve the functional outcome in patient with stroke.\textsuperscript{13,14,16} However, most of these trials were underpowered, started treatment too late after stroke onset, or aimed at only one specific complication after stroke. Strengths of PRECIOUS are the assessment in an elderly population with moderately severe to severe stroke (with an increased risk of complications and poor outcome), the start of treatment within 24 h after stroke onset, and its multifactorial design. The trial will provide high-quality evidence that could be broadly generalisable. Because of its pragmatic design and the use of safe, inexpensive, and generally available drugs, the results of PRECIOUS could be implemented rapidly throughout Europe and the rest of the world.

It may be questioned whether the effects of prophylactic antibiotics in patients with stroke should still be assessed after the neutral results in two recent phase III clinical trials. Ceftriaxone is an off-patent, broad-spectrum antibiotic with proven efficacy against bacteria most frequently causing infection in patients with acute stroke.\textsuperscript{12,27} In the PASS trial, 2550 patients with stroke were randomly assigned to standard care or intravenous ceftriaxone, started within 24 h of stroke onset, continued for four days. Preventive ceftriaxone reduced the incidence of infections in general (from 7% to 3%; \(p < 0.0001\)), but did not have an effect on the occurrence of pneumonia or the risk of a poor outcome at 90 days.\textsuperscript{16} However, the median score on the NIHSS of patients in PASS-was 5, which could explain the relatively low incidence of infections. In the cluster-randomised STROKE-INF trial, which included 1217 stroke patients with dysphagia, prophylactic antibiotics did not change the incidence of post-stroke pneumonia or poor functional outcome.\textsuperscript{17} However, antibiotic treatment may have started too late (up to 48 h after stroke onset) to prevent early infections. In addition, a considerable proportion of patients in the treatment group received only a limited number of antibiotic doses, while 34% of the patients in the control group received an antibiotic at least once during the first seven days. Finally, individual centres included only a small number of patients over an extended period of time; in a cluster-randomised study, this may induce selection bias decreasing the discriminative power.
Because of the limitations of these two trials, and the strong association between infections and a poor functional outcome,\textsuperscript{4,28} additional evidence on the effect of preventive antibiotics is still strongly needed.

The PRECIOUS trial will also be able to assess whether antibiotics work in isolation, or whether the effect is dependent on the combination of drugs that are used in the trial. The results of PASS and STROKE-INF support the concept that post-stroke pneumonia might be a respiratory syndrome resulting from complex bacterial, chemical and immunological causes that might not be prevented by antibiotics alone. The combination of treatments in PRECIOUS, especially the combination of metoclopramide and ceftriaxone, targets different pathways in the development of post-stroke pneumonia, potentially resulting in a larger reduction in the risk of complications than with the individual treatments alone.

The prevention of complications with the treatments proposed in PRECIOUS was safe in previous trials and not associated with an increased risk of SAEs.\textsuperscript{13,14,16} In addition, the risk of developing Clostridium difficile overgrowth was smaller than 1% in previous studies with ceftriaxone, and there was no association with an increase in antimicrobial resistance.\textsuperscript{16,17}

PRECIOUS uses paracetamol for the prevention of increases in body temperature because this was safe in doses up to 6 g per day in randomised clinical trials in patients with acute stroke, reduced the risk of subfebrile temperatures or fever at 24 h by 50% and was associated with a trend towards an improvement in functional outcome in the PAIS trial. This trial was underpowered to detect a benefit on functional outcome because this was terminated prematurely due to lack of funding after inclusion of 1400 patients, against a target of 2500 patients.\textsuperscript{10} For PRECIOUS, we have selected a maximum daily dose of 4 g to comply with the drug’s summary of product characteristics.

Given the potential benefit of the prevention of complications to the patients included in PRECIOUS, future stroke patients, their caregivers, and society, the risk-benefit balance is strongly in favour of conducting this clinical trial.

\textbf{Declaration of Conflicting Interests}

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Philip Bath is Stroke Association Professor of Stroke Medicine and is an NIHR Senior Investigator; Janika Körv has received fees as a consultant or lecture fees from Bayer, Pfizer, Boehringer Ingelheim, ReNeuron; Götz Thomalla has received fees as a consultant or lecture fees from Acandis, Bayer Vital, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Daichii Sankyo, GlaxoSmithKline, and Stryker and received a research grant from Bayer. Bart van der Worp has received speaker’s fees from Boehringer Ingelheim and Bayer; the other authors report no conflict of interest.

\textbf{Funding}

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: PRECIOUS has received funding from the European Union’s Horizon, 2020 research and innovation programme under grant agreement No 634809.

\textbf{Ethical approval}

The trial has been approved by national or local research ethics boards for all active clinical sites.

\textbf{Informed consent}

Not applicable

\textbf{Guarantor}

HBW.

\textbf{Contributorship}

All co-authors have contributed to the trial design, protocol development, and the writing of this manuscript.

\textbf{References}